Side Effects
Sermorelin has a well-established safety profile from its years as an FDA-approved medication. The following come from clinical trials and post-marketing experience.
Common (usually mild, self-limiting)
- Facial flushing - brief warmth/redness, usually resolving within 5-20 minutes
- Mild headache, most often in the first 1-2 weeks
Less common
- Nausea; drowsiness or restlessness
- Transient urticaria (hives); mild water retention
- Difficulty swallowing (rare); altered taste
Rare but significant
- Hypersensitivity reactions (facial swelling, breathing difficulty, anaphylaxis) - require immediate medical attention
- Anti-sermorelin antibody formation (common at least once in pediatric trials, often transient, generally without effect on growth outcomes)
What this evidence review covers
Summarize adverse effects and precautions from historical regulated-product research while distinguishing current product unknowns.
- Historical pediatric safety reporting
- Older-adult study limits
- Regulated product versus research-vial quality
- Population/indication mismatch
- Unknown current product risks
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
historical defined population
The pediatric study reported no adverse changes in the measured general biochemical or hormonal analyses and described treatment as generally well tolerated in that setting.
product boundary
Historical evidence cannot establish the safety profile of current research products, blends, or oral formulations.
| Evidence class | What the source supports |
|---|---|
| historical defined population | The pediatric study reported no adverse changes in the measured general biochemical or hormonal analyses and described treatment as generally well tolerated in that setting. |
| product boundary | Historical evidence cannot establish the safety profile of current research products, blends, or oral formulations. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
GHRH(1-29) therapy in growth-hormone-deficient children
Evidence class: primary open label multicenter historical. What it supports: Historical n=110 pediatric regulated-product protocol, growth-velocity outcomes, and reported short-term safety measures.
What it does not establish: Adult anti-aging, weight loss, current research-vendor products, or a modern self-treatment dose.
FDA orphan designation and marketing-approval record for Geref
Evidence class: primary regulatory historical. What it supports: The historical regulated-product approval record and approved pediatric context.
What it does not establish: Current market availability or equivalence of products labeled sermorelin by research vendors.
Questions this page answers
What side effects were reported historically?
Report only events and measurements in the cited study or historical label, with population and product context.
Is current Sermorelin research material proven safe?
No. Historical regulated-product evidence does not establish equivalence or current product quality.
What remains unresolved
- Current product-specific safety data absent.
- No adequate adult wellness safety evidence.
- A current authoritative label/withdrawal history should be verified before detailed contraindication copy.